Anthrax | A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Jul 10, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat anthrax.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180710005696/en/
Technavio has published a new report on the drug development pipeline for anthrax, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Anthrax: Market overview
Anthrax is an infectious disease caused by the bacterium Bacillus anthracis. Anthrax can develop when people breathe in spores, eat food, or drink water that is contaminated with spores, or get spores in a cut or scrape in the skin. It can occur in four forms, namely skin, lungs, intestinal, and injection and is developed by the bacterium’s spores, which often appear in infectious animal products. Therefore, people who work with animals and animal-based products and military and law enforcement personnel are at higher risk of developing anthrax. Anthrax is a life-threatening infectious disease, which can be cured with certain antibiotics.
According to a senior market research analyst at Technavio, “ Research studies shows that anthrax is more common in Central and South America, sub-Saharan Africa, Central and Southwestern Asia, and Southern and Eastern Europe. Cutaneous anthrax is the most commonly reported form of anthrax in humans.”
Anthrax: Segmentation analysis
This pipeline analysis report segments the anthrax market based on drugs under development (discovery, pre-clinical, phase I, and phase II), therapies employed (monotherapy and combination therapy), RoA (intranasal, intramuscular, oral, parenteral, intramuscular+intraperitoneal, and intravenous+oral), therapeutic modality (vaccine, small molecule, recombinant protein, and Lysin), targets (protective antigen, B. anthracis lethal factor, DNA polymerase, TLR9, bacterial type II topoisomerases, and peptidoglycan), MoA (immunostimulant, protective antigen inhibitor, B. anthracis lethal factor inhibitor, DNA polymerase inhibitors, TLR9 agonist, bacterial type II topoisomerases inhibitor, and peptidoglycan inhibitor), geographical segmentation covering the US and recruitment status (completed and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005696/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/10/2018 10:48 AM/DISC: 07/10/2018 10:48 AM